2023 World Conference on Lung Cancer (Posters)-EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center

EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to characterize KRAS mutations in Black patients with non-small cell lung cancer (NSCLC) at an urban academic medical center. KRAS is a common oncogenic driver of NSCLC, and two drugs, sotorasib and adagrasib, have recently been approved for the treatment of advanced KRAS G12C NSCLC. However, the representation of Black patients in clinical trials for these drugs was very low. <br /><br />The researchers conducted a retrospective review of patients with KRAS G12C NSCLC diagnosed over seven years at Northwestern Memorial Hospital. Out of the 75 patients identified, 61 met the inclusion criteria. Of these, 14.7% were Black, 80.3% were White, and the remaining were of other races or declined to provide their race. The average age at diagnosis was 65.2 years. <br /><br />Among the patients with stage IV disease, 13.5% were Black. PDL1 data was available for 51 patients, and among those with stage IV disease, 6 were Black and 38 were White. The distribution of PDL1 expression levels was similar between Black and White patients. <br /><br />The findings of this study suggest that there is a higher representation of Black patients with KRAS G12C NSCLC at the urban academic medical center compared to the clinical trials validating the therapies. It highlights the need for clinical trial sponsors to include medical centers that serve diverse patient populations to ensure equitable access to clinical trial involvement. Future studies should consider interventions to promote equitable access to clinical trials for all patients.

Asset Subtitle

Danielle Dressler

Meta Tag

Speaker Danielle Dressler

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

KRAS mutations

Black patients

non-small cell lung cancer

NSCLC

urban academic medical center

oncogenic driver

sotorasib

adagrasib

clinical trials

representation